Board to approve September quarter results on November 5

Net loss reportedEBITDA margin expansionRevenue declinedDebt to equity above the thresholdResults View source PDF Explain this filing

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹29.10

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.5%+0.7% vs market

Pharmaceuticals peers, median of 173sector-0.8%-1.0% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-2.5+0.7-0.8-1.0

Next day

+1.3-1.1+2.4-0.8+2.2

+0.1-0.8+1.0-0.5+0.6

+1.8+1.3+0.5+0.3+1.5

+5.8+2.5+3.4+1.3+4.5

-0.8pendingpending+1.4-2.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on November 5, 2026 to approve the company's unaudited standalone and consolidated results for the quarter ended September 30, 2026. Trading has been closed for directors, officers and designated employees since October 1 and will remain closed until 48 hours after the results are announced.

Likely market impact

No financial figures were provided. The results may affect stock sentiment after November 5, while insiders remain restricted for 48 hours after publication.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹79.39 Cr	₹106.9 Cr	−25.7%
Operating profit	−₹9.16 Cr	−₹25.49 Cr	loss narrowed
Profit after tax	−₹7.21 Cr	−₹21.14 Cr	loss narrowed
EBITDA margin	-1.4%	-6.8%	+5.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.